Breaking Finance News

Cowen and Company upgraded GenMark Diagnostics, Inc (NASDAQ:GNMK) to Outperform in a report released today.

Only yesterday GenMark Diagnostics, Inc (NASDAQ:GNMK) traded 16.44% higher at $8.82. GenMark Diagnostics, Inc’s 50-day moving average is $9.10 and its two hundred day moving average is $7.51. The last stock close is up 36.70% from the two hundred day moving average, compared with the S&P 500 which has decreased -0.01% over the same time period. 1,192,393 shares of GenMark Diagnostics, Inc traded hands, up from ann avg. volume of 286,652.

Cowen and Company has upgraded GenMark Diagnostics, Inc(NASDAQ:GNMK) to Outperform in a statement released 9/16/2016.

On 10/14/2015, Cowen reported about GenMark Diagnostics, Inc(NASDAQ:GNMK) lowered the target price from $15.00 to $11.00. At the time, this suggested an upside of 0.34%.

Performance Graphic:

GenMark Diagnostics, Inc (NASDAQ:GNMK)

GenMark Diagnostics, Inc has a one-year low of $4.20 and a 52 week high of $11.31 and has a total market value of $0.0.

More About GenMark Diagnostics, Inc (NASDAQ:GNMK)

GenMark Diagnostics, Inc. (GenMark) is a molecular diagnostics company. The Company focuses on developing and commercializing its eSensor detection technology. Its eSensor electrochemical technology detects multiple distinct biomarkers in a single sample. It sells its XT-8 instrument and related diagnostic and research tests (XT-8 system) in the United States. It has developed and intends to commercially launch its sample-to-answer ePlex instrument and its associated diagnostic tests, which it collectively refers to as its ePlex system, in Europe and the United States. It operates in the development, manufacturing, sales and support of instruments and molecular tests based on its eSensor detection technology segment. Over four of its diagnostic tests, which run on its XT-8 instrument, have received United States Food and Drug Administration clearance, including Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test, and Thrombophilia Risk Test and Respiratory Viral Panel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *